Max-delbruck-centrum Fur Molekulare Medizin

Forschungsverbund Berlin E.v.

Universidade Federal De Minas Gerais

Max-delbruck-centrum Fur Molekulare Medizin in Der Helmholtz-gemeinschaft

Max-delbruck-centrum Fur Molekularc Medizin

Max-delbruck-centrum Fur Molekulare Medizin Berlin-buch

Michael Bader

Edgar Specker

Susann Matthes

Anja Schütz

Keven Mallow

Maik Grohmann

Marc Nazaré

Natalia Alenina

Robson Augusto Souza Dos Santos

Mihail Todiras

Diego Walther

Rubens Dario Sinisterra

Luciana Rodriques Fernandez

Andrea Siqueira Haibara

Marina Matos De Moura

Jaqueline Isaura Alvarez Leite

Sergio Henrique Sousa Santos

Fatimunnisa Qadri

Silke Mühlstedt

Cemil ÖZcelik

Diego J Walther

A cosmetic method for modulating pigmentation in a subject includes administering a modulator of angiotensin-converting enzyme 2 (ACE2 modulator) to the subject. The ACE2 modulator can be an inhibitor of angiotensin-converting enzyme 2 (ACE2 inhibitor), in which case, the ACE2 inhibitor can be administered to increase pigmentation in the subject. The ACE2 modulator can also be an activator of angiotensin-converting enzyme 2 (ACE2 activator), in which case the ACE2 activator can be administered to decrease pigmentation in the subject. The treatment of inflammatory skin disease can also be achieved by inhibition of angiotensin-converting enzyme 2.

Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation

The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative.  The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same

The present invention is characterized by the use of Mas-G-protein-coupled receptor agonists for the control, prevention and treatment of the body levels of triglycerides, cholesterol and glucose, as well as of hyper-tension and possible increase in body weight, which are characteristic of the clinical manifestation of the metabolic syndrome and its complications. Another characteristic of the invention is the use of Mas-G-protein-coupled receptor agonists, including the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the manifestations of insulin resistance and glucose intolerance and in the prevention and treatment of the related alterations. The invention claims the use of MAS-G-protein-coupled receptor agonists, formulated with pharmaceutically and pharmacologically acceptable excipients or carriers, and Mas-G-protein-coupled receptor agonists, including the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the metabolic syndrome, the diseases that compose it and its complications.

Method for modulating, treating and/or preventing metabolic syndrome using MAS-G-protein-coupled receptor agonists

Pharmaceutical compositions for treatment of primary hemostasis deficiency and methods of treatment of primary hemostasis deficiency are disclosed. Also, methods for diagnosing neuronal diseases and for suppressing the immune system are disclosed. Isoforms responsible for maintaining primary hemostasis, T-cell mediated immune responses, neuron specific TPH, and a neuronal tryptophan hydroxylase are disclosed.

Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency

Growing community of inventors

Berlin, Germany

Michael Bader